OrbiMed Royalty Opportunities II, LP is a private equity fund based in New York, New York. According to its most recent Form D, filed Feb 2, 2015, it has sold $900,000,000 of interests to 83 investors since its first sale in Jan 2015. The minimum investment it accepts from an outside investor is $750,000. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Sven Borho; Jonathan Silverstein; Carl Gordon.
- Total raised
- $900,000,000Cumulative sales reported on Form D
- Investors
- 83
- First sale
- Jan 30, 2015
- Minimum investment
- $750,000
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Sven Borho; Jonathan Silverstein; Carl Gordon
- Latest Form D
- Feb 2, 2015
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about OrbiMed Royalty Opportunities II, LP
What is the minimum investment for OrbiMed Royalty Opportunities II, LP?
According to its latest Form D, filed Feb 2, 2015, the minimum investment OrbiMed Royalty Opportunities II, LP accepts from an outside investor is $750,000.
Who can invest in OrbiMed Royalty Opportunities II, LP?
OrbiMed Royalty Opportunities II, LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has OrbiMed Royalty Opportunities II, LP raised?
OrbiMed Royalty Opportunities II, LP reports $900,000,000 sold from 83 investors on its Form D filed Feb 2, 2015. This is cumulative sales since the offering began, not current assets or performance.
Where is OrbiMed Royalty Opportunities II, LP based?
OrbiMed Royalty Opportunities II, LP is based in New York, New York.
When did OrbiMed Royalty Opportunities II, LP launch?
OrbiMed Royalty Opportunities II, LP reports its first sale in Jan 2015.
Size compared with every private equity fund
Raised more than 94% of the 3,677 private equity funds based in New York, and more than 94% of all 8,983 that report sales.